Robert R. Redfield
Chief Scientific OfficerDr. Robert R. Redfield, M.D., is Chief Scientific Officer of Turn Therapeutics Inc. from September 2026. Dr. Redfield brings more than four decades of experience in immunology, microbiology, infectious disease, clinical research and public health. He has authored an extensive body of scientific literature cited more than 35,000 times, including research examining cytokine signaling and the biological interactions between pathogens and the host immune response. r. Redfield served for approximately two decades in the U.S. Army Medical Corps, where he conducted clinical and laboratory research at Walter Reed Army Medical Center and retired with the rank of Colonel. At Turn Therapeutics, Dr. Redfield will contribute toward the scientific and clinical strategy for GX-03 across atopic dermatitis, onychomycosis, hidradenitis suppurativa and potential additional indications. His work will focus particularly on cytokine signaling and the host inflammatory response to microbial stimulus, which is central to Turn Therapeutics’ therapeutic approach. Dr. Redfield will work closely with Burnam, Stephen M. Hahn, M.D., Turn Therapeutics Executive Clinical and Regulatory Lead and former Commissioner of the U.S. Food and Drug Administration and the Company’s clinical investigators and scientific advisors. Dr. Redfield served as the 18th Director of the U.S. Centers for Disease Control and Prevention from 2018 to 2021. Dr. Redfield is Chief Medical Officer of Traws Pharma, Inc. from April 1, 2024. Dr. Redfield was Acting Chief Medical Officer of Traws Pharma, Inc. Dr. Redfield serves as Chief Scientific Advisor since 2021 at Pasaca Capital, Inc. He served as Senior Medical Advisor at PersOwn, Inc. until July 2025. He has been the Head of Infectious Diseases at University of Maryland School of Medicine since June 2006. Dr. Redfield has been a Director of Centers for Disease Control and Prevention since March 2018. He oversees the clinical treatment of more than 4,000 HIV positive patients in the Baltimore/D.C. area as well as a treatment and care program under the President's Emergency Plan for AIDS Relief in nine African countries and the Caribbean. He serves as a Director of Clinical Care and Research for Institute for Human Virology. He co-founded the Institute of Human Virology in 1996 and serves as its Associate Director and Clinical Care & Research Director. He served as a Member of Advisory Board at Bionor Pharma ASA. He served as a Member of Scientific Advisory Board for Profectus Biosciences, Inc. He served as Member of Clinical Advisory Board of Bionor Immuno AS since October 2009. He served as Associate Director at Institute for Human Virology. He is a Professor of Medicine, Microbiology and Immunology for University of Maryland, Baltimore. Dr. Redfield is a pioneer in HIV clinical research, studies the newest and most effective biological treatments for HIV infection. Dr. Redfield earned his Bachelor of Science from Georgetown University’s College of Arts and Sciences and Doctor of Medicine from Georgetown University School of Medicine.
Positions
- Company NameTurn Therapeutics Inc.Stock CodeTTRXPositionChief Scientific OfficerColleagues
- BEBradley E. BurnamFounder, CEO & Director
- ZCZuraiz ChaudharyInterim CFO, VP of Finance & Chief Accounting Officer
- NSNeilesh Shailesh GhodadraChief Medical Officer & Director
- MZMohammed ZubairController
- AWAndrew W. GengosIndependent Director
- AFArthur F. GoldenIndependent Director
- MDMartin DewhurstIndependent Director
